DNA barcoding reveals cancer cells’ ability to evade the immune system
Using DNA barcoding to track cancer cells through time, scientists have shown that the cells have diverse abilities to escape the immune system.
List view / Grid view
Using DNA barcoding to track cancer cells through time, scientists have shown that the cells have diverse abilities to escape the immune system.
Pre-clinical experiments involving cells from ICUs patients infected by SARS-CoV-2, and mice infected by MHV-A59 (murine hepatitis virus A59) show promise in treating COVID-19.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
Dr Larysa Baraban, physicist at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) is researching a chip that should ultimately make it possible to develop personalised cancer immunotherapies.
Researchers have eradicated malignant tumours in mice by combining an immunotherapy agent with a molecular delivery system that targets tumour acidity.
Using cryo-EM, the researchers found that the B-cell receptor interacts with further receptors, thus controlling its signal transduction.
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
The scientists found the mechanism of drug resistance depends on activation of a protein called KDM1B which controls and regulates gene expression.
Researchers at the University of Arizona Health Sciences found that CD4 plays an active role in regulating T-cell receptor signalling.
Discover why the Hyperion+ Imaging System is the standard to assess tumour-immune interactions and get deep single-cell insights.
A report has shown that the immuno-oncology drug discovery outsourcing market is set to be worth $2563 million by 2030.
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
A new high-throughput approach has shown how patients whose tumours express CD58 are more likely to respond to CAR T-cell therapy.
Researchers have found how tumours can avoid the immune system and cancer immunotherapies, including CAR T-cell therapies.